Point72 Asset Management
GPCR icon

Point72 Asset Management’s Structure Therapeutics GPCR Stock Holding History

Point72 Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-407,700
Closed -$11.4M – 4001
2025
Q3 		$11.4M Buy
407,700
+77,700
+24% +$1.55M 0.02% 742
2025
Q2 		$6.84M Buy
330,000
+100,569
+44% +$2.21M 0.01% 867
2025
Q1 		$3.97M Sell
229,431
-247,267
-52% -$6.06M 0.01% 1011
2024
Q4 		$12.9M Sell
476,698
-761,570
-62% -$27M 0.03% 614
2024
Q3 		$54.3M Buy
1,238,268
+870,589
+237% +$33.7M 0.14% 173
2024
Q2 		$14.4M Buy
+367,679
New +$15.1M 0.04% 495
2023
Q4 		– Sell
-747,100
Closed -$37.7M – 2396
2023
Q3 		$37.7M Buy
747,100
+316,100
+73% +$10.2M 0.11% 235
2023
Q2 		$17.9M Buy
431,000
+81,138
+23% +$2.27M 0.05% 414
2023
Q1 		$8.32M Buy
+349,862
New +$8.22M 0.03% 603

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Point72 Asset Management's GPCR Position: Q4 2025 in Review

Point72 Asset Management sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 407,700 shares — an estimated $11.4M sold.

Point72 Asset Management first reported a position in GPCR in Q1 2023 and held it in 9 quarters. The position peaked at $54.3M in Q3 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

  • Point72 Asset Management reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 407,700 Structure Therapeutics shares in Q4 2025, an estimated $11.4M.
  • Point72 Asset Management first reported a position in Structure Therapeutics in Q1 2023 and held it in 9 quarters.
  • Point72 Asset Management's Structure Therapeutics position peaked at $54.3M in Q3 2024.
  • 197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.